**Scientists hot on SARS\' heels**

As the death toll from severe acute respiratory syndrome (SARS) mounts, scientists are swiftly amassing information about the virus causing the disease. As of 14 May, the World Health Organization (WHO) reported 7,548 probable SARS cases and 573 deaths in 30 countries. The disease first emerged last November in the Guangdong Province of China. WHO declared SARS a global health issue on 12 March.

A heightened immune response may underlie respiratory distress from lung damage in SARS patients, doctors say. A statistical analysis of 1,425 suspected SARS patients in Hong Kong revealed that the death rate from SARS is about 55% in people over 60 and up to 13.2% in younger people. Scientists are also considering the possibility that the elderly, and those already battling other ailments, are particularly infectious. These \'superspreaders\' are rare carriers who can infect 10 or more people.

The virus is mutating slowly as it spreads, say Singaporean researchers, dashing hopes that it might weaken over generations but boosting confidence in an effective vaccine. Corporate and government labs around the world are already working on a SARS vaccine. Scientists at the Center for Virus Research at the University of California in Irvine, for example, plan to begin primate studies of their vaccine candidate at the end of May. *PB*

**Malaria programs face financial crisis**

The Roll Back Malaria Initiative, which pledged to halve global malaria cases by 2010, is coping with a funding shortage, according to a report by the World Health Organization and the United Nations Children\'s Fund. At the same time, 3,000 African children succumb to malaria every day, according to the agencies\' \'Africa Malaria Report\'.

Since its 1998 launch, the initiative has reported raising malaria funds of up to \$200 million a year. But an independent study by Harvard University researchers reports that donor surveys reflect otherwise. Actual funds for combating malaria from loans and international aid stand at \$98.9 million, according to the study; current malaria funding is less than 7% of what is needed, widely estimated at about \$1.5-\$2 billion.

The year-old Global Fund to Fight AIDS, Tuberculosis and Malaria is also financially troubled. Federal investigators reported on 7 May that the fund holds just \$300 million. Grant applications for the fund are due at the end of May, however, and are expected to cumulatively request \$1.6 billion. *PB*

**Avian flu spreads its wings in Europe**

Even before severe acute respiratory syndrome dominated world headlines, an avian influenza virus emerged in the Netherlands in late February before spilling into Belgium and, more recently, Germany. As of 14 May, the virus---dubbed H7N7---had rapidly spread through poultry farms and caused conjunctivitis and mild flu symptoms in 83 people. It also contributed to the death of a Dutch veterinarian.**Bird\'s-eye view:** Dutch veterinarians take DNA samples on a farm after an outbreak of bird flu.Michael Kooren/Reuters

Most of those infected worked near the afflicted farms. But infections in some of their family members---now known to be unrelated human influenza cases---prompted concerns that bird and human flu viruses might have mingled to produce a new strain that is transmissible among humans. All reported infections thus far have been derived from primary contact with birds, but concerns about a mixed virus remain, says Nancy Cox, chief of the influenza branch of the US Centers for Disease Control and Prevention.

The European Union has banned all sales and exports of live poultry, eggs and bird meat from the Netherlands, where up to 25 million chickens will be culled. Tens of thousands of chickens have been killed in Belgium and another 81,000 in northwest Germany. Health care workers culling the birds are in protective gear and are taking the antiviral drug oseltamivir, says Cox. Meanwhile, the World Health Organization is working on a vaccine, as well as a test kit to help spot new infections. *PB*

**Gates open for Grand Challenge grant proposals**

The Grand Challenges in Global Health Initiative on 2 May called for researchers worldwide to help identify the most difficult scientific obstacles in improving global health. Once ideas are submitted by the 15 June deadline, members of the initiative\'s scientific board will select up to 15 "official Grand Challenges," says Harold Varmus, chairman of the board.

The initiative was first launched in January, with a \$200 million grant from the Bill and Melinda Gates Foundation in partnership with the US National Institutes of Health (NIH). The chosen challenges will include innovations from any scientific field that may help counteract diseases that devastate developing countries.

The NIH is making use of e-mail, journal advertisements and word of mouth to make sure even researchers in remote corners of the world hear about the initiative, says Elke Jordan, the initiative\'s NIH-based manager. Board members will announce the chosen challenges on 1 October and will simultaneously solicit grant proposals from teams of scientists. *PB*

**Europe seeks clarity on stem cell decision**

The European Commission is set to submit in June a new proposal for regulating research with human embryonic stem cells (ESCs). The funding has thus far been at an impasse because of radically different positions taken by member countries. If opinions heard at a bioethics seminar---held in Brussels on 24 April---are any indication, reconciliation is nowhere in sight.

Last summer, the European Union\'s Council of Science Ministers adopted a unilateral decision not to finance research on human ESCs with funds from the sixth Framework Programme. But complaints from the European Parliament prompted new negotiations. Last September, the commission decided that, pending a new proposal, it would only fund projects with established stem cell lines. It will review its decision, based on the new proposal, by December of this year.

While discussions in the commission are stalled, member countries are pushing ahead on their own. In April, the Belgian Parliament passed new legislation permitting therapeutic cloning and human ESC research; the UK patent office now allows patents on work with human ESCs; and the Spanish national committee on sciences in March recommended that the government allow human ESC research. *XB*
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